William Michael Kavanaugh
Director/Board Member presso AmMax Bio, Inc.
Profilo
William Michael Kavanaugh is an Independent Director at AmMax Bio, Inc. and an Associate Clinical Professor-Medicine at The University of California, San Francisco.
He previously worked as a Director at Inova Loudoun Hospital, Inc., VP, Head-Antibody & Protein Therapeutics Research at Chiron Corp., Vice President at Novartis Vaccines & Diagnostics, Inc., Executive Director & Head-Biological Therapeutics at Novartis Institutes for Biomedical Research, Inc., Chief Scientific Officer & Senior VP-Research at Five Prime Therapeutics, Inc., and Chief Scientific Officer, SVP & Head-Research at CytomX Therapeutics, Inc. Kavanaugh holds a doctorate from Vanderbilt University and an undergraduate degree from Yale University.
Posizioni attive di William Michael Kavanaugh
| Società | Posizione | Inizio |
|---|---|---|
| The University of California, San Francisco | Corporate Officer/Principal | - |
AmMax Bio, Inc.
 AmMax Bio, Inc. BiotechnologyHealth Technology AmMax Bio, Inc. is a clinical stage biotech company. The private company is based in Redwood City, CA. The CEO of the company is Chung Chiang Hsu. | Director/Board Member | 24/02/2022 |
Precedenti posizioni note di William Michael Kavanaugh
| Società | Posizione | Fine |
|---|---|---|
| CYTOMX THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 01/12/2020 |
| FIVE PRIME THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 01/12/2014 |
Novartis Institutes for Biomedical Research, Inc.
 Novartis Institutes for Biomedical Research, Inc. Miscellaneous Commercial ServicesCommercial Services Novartis Institutes for Biomedical Research, Inc. conducts biomedical researches. It focuses in the areas of oncology, ophthalmology, diabetes, musculoskeletal disorders, neuroscience, and cardiovascular conditions, other focus areas include discovery chemistry, biologics, pathway biology, and translational medicine. The company was founded on September 10, 2002 and is headquartered in Cambridge, MA. | Director/Board Member | 01/02/2009 |
Chiron Corp.
 Chiron Corp. Medical SpecialtiesHealth Technology Chiron Corp. provides nucleic acid test for blood screening. Its products include tigris system, target capture system, reagent preparation incubator, and many more. The company was founded in 1981 by William J. Rutter, Edward E. Penhoet & Pablo Valenzuela and is headquartered in Emeryville, CA. | Corporate Officer/Principal | - |
Novartis Vaccines & Diagnostics, Inc.
 Novartis Vaccines & Diagnostics, Inc. Pharmaceuticals: MajorHealth Technology Novartis Vaccines & Diagnostics, Inc. manufactures and markets health care and nutritional products. The company was founded in 1986 and is headquartered in East Hanover, NJ. | Corporate Officer/Principal | - |
Formazione di William Michael Kavanaugh
| Vanderbilt University | Doctorate Degree |
| Yale University | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| CYTOMX THERAPEUTICS, INC. | Health Technology |
| Aziende private | 6 |
|---|---|
Chiron Corp.
Chiron Corp. Medical SpecialtiesHealth Technology Chiron Corp. provides nucleic acid test for blood screening. Its products include tigris system, target capture system, reagent preparation incubator, and many more. The company was founded in 1981 by William J. Rutter, Edward E. Penhoet & Pablo Valenzuela and is headquartered in Emeryville, CA. | Health Technology |
Five Prime Therapeutics, Inc.
 Five Prime Therapeutics, Inc. BiotechnologyHealth Technology Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of novel protein therapeutics. Its product candidates includes, Cabiralizumab (FPA008), Bemarituzumab (FPA144), and FPA150. The FPA008 is an antibody that inhibits colony stimulating factor-1, or CSF1, receptor, or CSF1R, that are developing in rheumatoid arthritis and plan to clinically develop in pigmented villonodular synovitis, or PVNS, and in combination with nivolumab in multiple cancers. The FPA144 is an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, that are developing to treat patients with gastric cancer. The FPA150 is a CD8 T cell checkpoint which targets B7-H4 that is developing as a monotherapy in multiple cancers. The company was founded by Lewis T. Williams in December 2001 and is headquartered in South San Francisco, C. | Health Technology |
Inova Loudoun Hospital, Inc.
 Inova Loudoun Hospital, Inc. Hospital/Nursing ManagementHealth Services Inova Loudoun Hospital, Inc. provided medical and health care services. The firm offered services such as rehabilitation, general medicine, pediatric, intensive care, cancer care, cardiac care, ambulatory surgical and other diagnostic services. The company was founded in 1912 and was headquartered in Leesburg, VA. | Health Services |
Novartis Vaccines & Diagnostics, Inc.
Novartis Vaccines & Diagnostics, Inc. Pharmaceuticals: MajorHealth Technology Novartis Vaccines & Diagnostics, Inc. manufactures and markets health care and nutritional products. The company was founded in 1986 and is headquartered in East Hanover, NJ. | Health Technology |
Novartis Institutes for Biomedical Research, Inc.
Novartis Institutes for Biomedical Research, Inc. Miscellaneous Commercial ServicesCommercial Services Novartis Institutes for Biomedical Research, Inc. conducts biomedical researches. It focuses in the areas of oncology, ophthalmology, diabetes, musculoskeletal disorders, neuroscience, and cardiovascular conditions, other focus areas include discovery chemistry, biologics, pathway biology, and translational medicine. The company was founded on September 10, 2002 and is headquartered in Cambridge, MA. | Commercial Services |
AmMax Bio, Inc.
AmMax Bio, Inc. BiotechnologyHealth Technology AmMax Bio, Inc. is a clinical stage biotech company. The private company is based in Redwood City, CA. The CEO of the company is Chung Chiang Hsu. | Health Technology |
- Borsa valori
- Insiders
- William Michael Kavanaugh
